

Quality Research in Radiation Oncology
2607 Prostate Process

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:

Form I 1

Staging - Labs/Imaging

1. Last pre-treatment PSA level _____ ng/ml (999. = *unknown*)

2. CT scan _____
1 = No
2 = Yes
9 = Unknown

3. MRI _____
1 = No
2 = Yes
9 = Unknown

4. Bone scan _____
1 = No
2 = Yes
9 = Unknown

5. ProstaScint scan _____
1 = No
2 = Yes
9 = Unknown

Quality Research in Radiation Oncology
2607 Prostate Process

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:
Form I 1

Pathology

6. Method of diagnosis _____
1 = US - guided needle biopsy
2 = TURP (Transurethral Resection of the prostate)
8 = Other
9 = Unknown

Prostate Biopsy:

7. Total # of cores taken: _____ (88 = not reported; 99 = unknown)
8. Total # of positive cores: _____ (88 = not reported; 99 = unknown)
9. Maximum percent of cancer tissue in the core with the highest Gleason score _____ %
(888 = not reported; 999 = unknown)

Gleason Score:

10. Gleason Grade (GG) - primary _____ (8 = not reported; 9 = unknown)
11. Gleason Grade (GG) - secondary _____ (8 = not reported; 9 = unknown)
12. Gleason Score (GS) _____ (88 = not reported; 99 = unknown)
(Combined primary and secondary grade)

If no Gleason Score:

13. Histological differentiation _____
1 = Well-differentiated (Grade 1)
2 = Moderately well-differentiated (Grade 2)
3 = Poorly-to-very poorly differentiated (Grades 3-4)
9 = Unknown

**Quality Research in Radiation Oncology
2607 Prostate Process**

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:
Form I 1

Stage/Extent of Disease

14. Digital Rectal Exam (DRE) done by radiation oncologist _____
 1 = No
 2 = Yes
 9 = Unknown
15. T Classification _____
 1 = TX = Primary tumor cannot be assessed
 2 = T0 = No evidence of primary tumor
 3 = T1 = Clinically in-apparent tumor neither palpable nor visible by imaging
 4 = T1a = Tumor incidental - histological finding in 5% or less of tissue resected
 5 = T1b = Tumor incidental - histological finding in more than 5% or less of tissue resected
 6 = T1c = Tumor identified by needle biopsy (e.g. because of elevated PSA)
 7 = T2 = Tumor confined within prostate
 8 = T2a = Tumor involves one-half of one lobe or less
 9 = T2b = Tumor involves more than one-half of one lobe but not both lobes
 10 = T2c = Tumor involved both lobes
 11 = T3 = Tumor extends through prostate capsule
 12 = T3a = Extra-capsular extension (unilateral or bilateral)
 13 = T3b = Tumor invades seminal vesicle(s)
 14 = T4 = Tumor is fixed or invades other adjacent structures other than seminal vesicles: (e.g. *Bladder neck, external sphincter, rectum, levator muscles and/or pelvic walls*)
 99 = Unknown
16. Was nodal biopsy done? _____
 1 = No
 2 = Yes, FNA
 3 = Yes, lymph node dissection
 4 = Yes, both FNA & lymph node dissection
 9 = Unknown
17. Number positive nodes _____ (99 = unknown)
18. N Classification _____
 0 = NX = Regional lymph nodes were not assessed
 1 = N0 = No regional lymph node metastasis
 2 = N1 = Metastasis in regional lymph node(s)
 9 = Unknown

Quality Research in Radiation Oncology
2607 Prostate Process

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:
Form I 1

Treatment Summary

19. Investigational protocol _____
1 = No
2 = Yes, NCI Clinical Trials Cooperative Group (*specify below*)
3 = Yes, IRB-approved institutional clinical trial
4 = Yes, IRB-approved PHARMA clinical trial
5 = Yes, IRB-approved device clinical trial
8 = Other
9 = Unknown

If question #19 is Yes, NCI Clinical Trials Cooperative Group, (code 2):

20. Protocol group & number are (e.g., RTOG 9709) _____ (9999 = *Unknown*)

Treatment:

23. Orchiectomy _____
1 = No
2 = Yes
9 = Unknown
24. History of (TURP) Transurethral resection of the prostate _____
1 = No
2 = Yes
9 = Unknown
25. Endocrine manipulation _____
1 = No
2 = Yes
9 = Unknown

If yes,

26. (DES) Diethylstilbestrol _____
1 = No
2 = Yes
9 = Unknown
27. LHRH (Luteinizing hormone-releasing hormone) agonist _____
1 = No
2 = Yes
9 = Unknown

Quality Research in Radiation Oncology
2607 Prostate Process

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:

Form I 1

28. Androgen blocker _____

1 = No

2 = Yes, short term (< 6 months)

3 = Yes, long term (> = to 6 months)

9 = Unknown

30. Other hormonal manipulation _____

1 = No

2 = Yes

9 = Unknown

31. Planned duration of hormonal therapy (months): _____

(Longest duration of any endocrine therapy)

(777.=On-going; 778.=Short-term; 888.=Duration cannot be determined; 999.=Unknown)

32. Chemotherapy _____

1 = No

2 = Yes

9 = Unknown

**Quality Research in Radiation Oncology
2607 Prostate Process**

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:

Form I 1

External Beam RT

34. Any external beam RT? _____
1 = No
2 = Yes, at other facility
3 = Yes, at this facility
4 = Yes, at both other and this facility
9 = Unknown
35. If yes, at other facility (code 2 or 4), name of facility _____
36. Other facility's data available _____
1 = No
2 = Yes
9 = Unknown
37. CT used in external beam treatment planning _____
1 = No
2 = Yes
9 = Unknown
38. MRI used in external beam treatment planning _____
1 = No
2 = Yes
9 = Unknown
39. Equipment _____
1 = Linear accelerator
2 = TomoTherapy
3 = Proton
4 = Cyberknife
8 = Other
9 = Unknown
40. Energy _____ MV (*record maximum energy*)
(99=*unknown*)

Quality Research in Radiation Oncology 2607 Prostate Process

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:
Form I 1

41. Was IMRT used? _____
1 = No
2 = Yes
9 = Unknown
42. Was some form of immobilization used? _____
1 = No
2 = Yes, external
3 = Yes, internal
4 = Yes, external and internal
9 = Unknown
43. Daily target localization _____
1 = Fiducial markers with imaging
2 = Electronic portal imaging (for bony anatomy landmarks)
3 = Film portal imaging (for bony anatomy landmarks)
4 = Calypso
5 = CT imaging
6 = TomoTherapy
7 = Transabdominal Ultrasound
8 = None of the above
9 = Unknown
44. DVH (dose volume histogram) information recorded for target and normal tissue structures? _____
1 = No
2 = Yes
9 = Unknown

If yes, for which structure was a DVH generated and found in chart?

45. Prostate _____
1 = No
2 = Yes
46. Rectum _____
1 = No
2 = Yes
47. Bladder _____
1 = No
2 = Yes

**Quality Research in Radiation Oncology
2607 Prostate Process**

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:
Form I 1

External Beam RT Details

| Technique 0 = Not applicable 1 = 2D 2 = 3D 3 = IMRT 8 = Other 9 = Unknown | | | | |
|--|-----------|-------------------------------|----------------------------|-----------------------------------|
| Region | Technique | Dose/Fx (cGy) (999=unk) | # of Fractions (99=unk) | Total Dose (cGy) (9999=unk) |
| Prostate & seminal vesicles & nodes | _____ 48 | _____ 49 | _____ 50 | _____ 51 |
| Prostate & nodes | _____ 52 | _____ 53 | _____ 54 | _____ 55 |
| Prostate & seminal vesicles | _____ 56 | _____ 57 | _____ 58 | _____ 59 |
| Prostate alone | _____ 60 | _____ 61 | _____ 62 | _____ 63 |
| Nodes alone | _____ 64 | _____ 65 | _____ 66 | _____ 67 |
| Other/ Unknown If Other, specify _____ 68 | _____ 69 | _____ 70 | _____ 71 | _____ 72 |

**Quality Research in Radiation Oncology
2607 Prostate Process**

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:

Form I 1

Brachytherapy

73. Brachytherapy (Interstitial implant) _____

- 1 = No
- 2 = Yes
- 9 = Unknown

If yes,

74. Where was Brachytherapy done? _____

- 2 = At other facility
- 3 = At this facility
- 4 = At both other and this facility
- 9 = Unknown

75. If other facility, (code 2), name of other facility _____

76. Other facility's data available _____

- 1 = No
- 2 = Yes
- 9 = Unknown

77. Prostate volume at time of implant: _____ (cc) (999. = unknown)

78. Imaging used for brachytherapy treatment planning _____

- 1 = No
- 2 = Yes
- 9 = Unknown

79. *If yes:* _____

- 1 = TRUS (Transrectal ultrasound)
- 2 = CT (Computerized tomography)
- 3 = MRI
- 8 = Other
- 9 = Unknown

80. Imaging used for implant procedure _____

- 1 = No
- 2 = Yes
- 9 = Unknown

81. *If yes:* _____

- 1 = TRUS (Transrectal ultrasound)
- 2 = Fluoroscopy
- 3 = Both, TRUS and Fluoroscopy
- 4 = CT (Computerized tomography)
- 5 = MRI
- 8 = Other
- 9 = Unknown

82. *If other, specify* _____

Quality Research in Radiation Oncology
2607 Prostate Process

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:
Form I 1

Brachytherapy O.R.

83. Location of procedure room _____
1 = Operating room inside hospital
2 = Freestanding surgical center
8 = Other
9 = Unknown
84. *If other, specify* _____
88. Method of anesthesia _____
1 = General anesthesia
2 = Spinal anesthesia
3 = Local anesthesia
8 = Other
9 = Unknown
89. *If other, specify* _____
90. Cystoscopy performed intraoperatively _____
1 = No
2 = Yes
9 = Unknown
91. Post-implant care _____
1 = Planned outpatient with immediate discharge
2 = Inpatient hospitalization (<24 hours)
3 = Inpatient hospitalization (≥24 hours)
8 = Other
9 = Unknown
92. *If other, specify* _____
93. Foley catheter required >24 hours after brachytherapy procedure _____
1 = No
2 = Yes
9 = Unknown

**Quality Research in Radiation Oncology
2607 Prostate Process**

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

**Institution #:
Form I 1**

Brachytherapy - LDR

94. Low Dose Rate (LDR) _____

- 1 = No
- 2 = Yes
- 9 = Unknown

If No or Unknown, skip to Q107

95. Isotope utilized _____

- 1 = Iodine-125
- 2 = Palladium-103
- 3 = Gold-198
- 4 = Cs-131
- 8 = Other
- 9 = Unknown

96. *If other, specify* _____

97. LDR planning technique _____

- 1 = Preoperative planning onsite
- 2 = Intraoperative planning
- 8 = Other
- 9 = Unknown

98. *If other, specify* _____

99. Source loading _____

- 1 = Loose seeds, preloaded needles
- 2 = Seeds embedded in suture material, preloaded needles
- 3 = Mick applicator
- 4 = Loose seeds and seeds embedded in suture material
- 8 = Other
- 9 = Unknown

100. *If other, specify* _____

101. Number of sources placed _____ (999 = unknown)

102. Activity/source (mCi/source) _____ (9. = unknown)

103. Total activity placed (mCi) _____ (999. = unknown)

104. Sources assayed on site _____

- 1 = No
- 2 = Yes
- 9 = Unknown

Quality Research in Radiation Oncology
2607 Prostate Process

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:

Form I 1

105. Brachytherapy prescription dose to the prostate
(entire gland or periphery): _____ (cGy) (99999 = *unknown*)

106. Post-implant dosimetry _____
1 = None
2 = Orthogonal radiographs
3 = CT (Computerized tomography)
4 = MRI
5 = Ultrasound
8 = Other
9 = Unknown

**Quality Research in Radiation Oncology
2607 Prostate Process**

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

**Institution #:
Form I 1**

| |
|----------------------------|
| Brachytherapy - HDR |
|----------------------------|

107. High Dose Rate (HDR): _____

- 1. No
- 2. Yes
- 9. Unknown

If No or Unknown, skip to next section (Q151)

If yes to HDR:

| Application Number* | Isotope Utilized 1 = Ir192 8 = Other 9 = Unknown | # of Fractions (99=unk) | Dose/Fraction (cGy) (9999=unk) | Minimum Interval Between Fractions 1 = 0 - <4 hrs 2 = 4 - 6 hrs 3 = > 6 hrs 9 = Unknown | Total Prescription Dose w/ HDR (cGy) (9999=unk) |
|---------------------|---|----------------------------|--------------------------------------|--|--|
| 1 | _____ 108 <i>If other, specify:</i> _____ 109 | _____ 110 | _____ 111 | _____ 112 | _____ 113 |
| 2 | _____ 114 <i>If other, specify:</i> _____ 115 | _____ 116 | _____ 117 | _____ 118 | _____ 119 |
| 3 | _____ 120 <i>If other, specify:</i> _____ 121 | _____ 122 | _____ 123 | _____ 124 | _____ 125 |

* (Needle inserted is one application. Applications separated by 2 weeks)

Quality Research in Radiation Oncology
2607 Prostate Process

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:
Form I 1

GENERAL COMMENTS

Use multiple lines, as needed.

Note: DO NOT include any Personal Health Information (PHI) in these comments.

151. _____

152. _____

153. _____

154. _____

155. _____

156. _____

157. _____

158. _____

159. _____

160. _____

**Quality Research in Radiation Oncology
2607 Prostate Process**

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

**Institution #:
Form I 1**

| |
|-------------------------------------|
| Adult Comorbidity Evaluation |
|-------------------------------------|

200. Comorbidities _____
 1 = No comorbidities 2 = Yes, one or more 9 Cannot be determined

| Comorbidity | Grade: 0 = None 1 = Grade 1 (<i>mild</i>) 2 = Grade 2 (<i>mod</i>) 3 = Grade 3 (<i>severe</i>) 4 = Present, grade unknown 9 = Unknown |
|--|---|
| Cardiovascular system comorbidity score (Including MI, angina / CAD, CHF, arrhythmias, HTN, venous and peripheral arterial disease) | 201. _____ |
| Respiratory system comorbidity score (Including pulmonary insufficiency, and restrictive lung disease or COPD) | 202. _____ |
| Gastrointestinal system comorbidity score (Including hepatic disease, stomach/intestine, and pancreatic disease) | 203. _____ |
| Renal system comorbidity score (End stage renal disease) | 204. _____ |
| Endocrine system comorbidity score (Including Insulin dependent diabetes mellitus, and adult onset diabetes mellitus) | 205. _____ |
| Neurological system comorbidity score (Including stroke, dementia, paralysis, and neuromuscular disorders) | 206. _____ |
| Psychiatric comorbidity score (Including major depression, bipolar disorder, and schizophrenia) | 207. _____ |
| Rheumatologic comorbidity score (Including rheumatoid arthritis, systemic lupus, connective tissue disorder, and polymyositis) | 208. _____ |
| Immunological system comorbidity score (HIV, and AIDS) | 209. _____ |
| Malignancy comorbidity score (Solid tumors including melanoma, leukemia, myeloma, and lymphoma) | 210. _____ |
| Substance Abuse comorbidity score (Including alcohol abuse, illicit drug abuse) | 211. _____ |
| Body weight comorbidity score (Obesity, BMI >= 38) | 212. _____ |

213. Was treatment contra-indicated or changed due to comorbidities?
 No Yes Unknown

**Quality Research in Radiation Oncology
2607 Prostate Process**

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:

Form I 1

Sequence of Events

All dates will be blanked out before data are transmitted to the database. Only Elapsed days and Duration will be retained.

| Events | <i>mm/dd/yyyy</i> | Elapsed days* | Duration (days) |
|--------------------------------------|----------------------|---------------|-------------------------|
| <u>Staging- Labs/Imaging:</u> | | | |
| Last pre-treatment PSA performed: | 222. ___ / ___ / ___ | 223. _____ | |
| <u>Pathology:</u> | | | |
| Original diagnosis: | 224. ___ / ___ / ___ | 225. _____ | |
| <u>Treatment Summary:</u> | | | |
| Start of first Systemic** therapy: | 226. ___ / ___ / ___ | 227. _____ | |
| Start of External Beam therapy: | 228. ___ / ___ / ___ | 229. _____ | |
| Completion of External Beam therapy: | 230. ___ / ___ / ___ | 231. _____ | 232. _____ (231-229) |
| <u>Brachytherapy – LDR:</u> | | | |
| Placement of sources: | 238. ___ / ___ / ___ | 239. _____ | |
| Post-implant dosimetry: | 240. ___ / ___ / ___ | 241. _____ | |
| <u>Brachytherapy – HDR:</u> | | | |
| First HDR fraction: | 242. ___ / ___ / ___ | 243. _____ | |
| Last HDR fraction: | 244. ___ / ___ / ___ | 245. _____ | 246. _____ (245-243) |

* Elapsed time (in days) for an event is the date of that event minus the reference date.

** The earlier of hormonal therapy or chemotherapy.

Quality Research in Radiation Oncology
2607 Prostate Process

American College of Radiology 1818 Market Street, Suite 1600 Philadelphia, PA 19103 215-574-3164

Case #:

Institution #:

Form I 1

SOE COMMENTS:

Use multiple lines, as needed.

Note: DO NOT include any Personal Health Information (PHI) in these comments.

250. _____

251. _____

252. _____

253. _____

254. _____

255. _____

256. _____

257. _____

258. _____

259. _____